Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NYSE:BVF
- CUSIP: N/A
- Web: www.valeant.com/
- Trailing P/E Ratio: N/A
- P/E Growth: N/A
- Net Margins: 29.82%
- Return on Equity: 71.51%
- Return on Assets: 5.88%
Frequently Asked Questions for Valeant Pharmaceuticals Intl (NYSE:BVF)
What is Valeant Pharmaceuticals Intl's stock symbol?
Valeant Pharmaceuticals Intl trades on the New York Stock Exchange (NYSE) under the ticker symbol "BVF."
Who are some of Valeant Pharmaceuticals Intl's key competitors?
Some companies that are related to Valeant Pharmaceuticals Intl include Johnson & Johnson (JNJ), Novartis AG (NVS), Pfizer (PFE), Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), Abbott Laboratories (ABT), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY) and Valeant Pharmaceuticals International (VRX).
Who are Valeant Pharmaceuticals Intl's key executives?
Valeant Pharmaceuticals Intl's management team includes the folowing people:
- Joseph C. Papa, Chairman of the Board, Chief Executive Officer
- Paul S. Herendeen, Chief Financial Officer, Executive Vice President
- Christina Ackermann, Executive Vice President, General Counsel
- Thomas J. Appio, Executive Vice President, Company Group Chairman, International
- William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology
- Thomas W. Ross Sr, Lead Independent Director
- Richard U. DeSchutter, Independent Director
- Fredric N. Eshelman, Independent Director
- D. Robert Hale, Independent Director
- Argeris N. Karabelas Ph.D., Independent Director
How do I buy Valeant Pharmaceuticals Intl stock?
MarketBeat Community Rating for Valeant Pharmaceuticals Intl (NYSE BVF)MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shares of Valeant Pharmaceuticals Intl can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
Consensus Ratings for Valeant Pharmaceuticals Intl (NYSE:BVF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Valeant Pharmaceuticals Intl (NYSE:BVF)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Valeant Pharmaceuticals Intl (NYSE:BVF)
Latest Headlines for Valeant Pharmaceuticals Intl (NYSE:BVF)
Valeant Pharmaceuticals Intl (BVF) Chart for Wednesday, June, 28, 2017